Mesoblast Limited vs Super Micro Computer Inc — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Super Micro Computer Inc trades at $37.27 (market cap $20.44B). The key difference: Super Micro Computer Inc is far larger — about 9.2× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | SMCI | |
|---|---|---|
Market Cap | $2.21B | $20.44B |
Sector | Technology | Technology |
52-Week High | $20.96 | $58.68 |
52-Week Low | $12.88 | $20.53 |
Enterprise Value | $2.21B | $27.96B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Super Micro Computer (SMCI) stock trades at $37.55, up 19.4% on strong Q4 2026 earnings that beat estimates with EPS of $1.70 versus $0.923 expected. The company reported 93% revenue growth year-over-year and issued aggressive fiscal 2027 revenue guidance of $65–72 billion. Technical indicators show a bullish trend with moving averages supporting upside, while RSI levels suggest potential overbought conditions near-term.
The outlook remains positive driven by robust AI infrastructure demand, but risks include execution challenges in meeting high growth targets and competitive pressures. Analyst consensus is a Buy with a $40.40 price target, indicating 7.6% upside from current levels, though margin compression and supply chain delays pose headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →